# Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-and-tolerability-evaluation-of-sintilimab-in-combination-with-low-dose/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Rutao Li,L. Chen,Yan Zhang,L.Y. Mei,Laiyan Zhou,Xiaodong Zhu,Min Yu,L. Yin,Youling Gong,Jianxin Xue,You Lü |
| Citations | 3 |
| DOI | 10.1016/j.ijrobp.2020.07.2215 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3094364238 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Rutao Li](https://scholariq.org/researchers/rutao-li/)

## Paper journal

- [International Journal of Radiation Oncology*Biology*Physics](https://scholariq.org/journals/international-journal-of-radiation-oncology-biology-physics/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.